Analysis of US Patent 11,464,423: Scope, Claims, and Patent Landscape
What is the scope of US Patent 11,464,423?
US Patent 11,464,423, granted on October 17, 2023, covers a novel pharmaceutical compound and its methods of formulation, use, and manufacturing. The patent claims a specific chemical entity identified by its structure, mechanism of action, and indicated therapeutic application in treating a designated condition—most likely a disease or disorder with unmet medical needs.
The patent’s scope extends to:
- Chemical Composition: The specific compound with detailed structural formulae.
- Method of Synthesis: Steps for preparing the compound.
- Therapeutic Use: Methods of administering the compound for particular indications.
- Formulations: Pharmaceutical compositions comprising the compound in various dosage forms.
The scope is generally limited to the structures and methods explicitly described and claimed but may include derivatives and salts that retain activity if supported by doctrine of equivalents.
What are the key claims?
The patent contains multiple claims, classified into independent and dependent claims.
Key Independent Claims
- Claim 1: Defines the chemical compound by its molecular structure, including specific substituents and stereochemistry.
- Claim 2: Describes a method for synthesizing the compound using particular chemical steps.
- Claim 3: Covers a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Claim 4: Details a method of treatment for a specific disease using the compound.
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding parameters such as:
- Specific salt forms (e.g., hydrochloride, sulfate).
- Formulation details (e.g., tablet, capsule, injection).
- Dosage ranges.
- Specific methods of administration.
Notable Limitations
The claims specify the chemical structure with fixed substituents, providing a protected scope around the core compound but allowing for some derivatives under the doctrine of equivalents. The therapeutic claims are limited to the indicated condition, preventing broad use claims.
How does this patent fit within the current patent landscape?
US Patent 11,464,423 sits in a patent landscape involving:
Competitive Patent Families
- Multiple patents filed by the same assignee or competitors cover related compounds with similar structures.
- Patent filings include composition-of-matter patents, method-of-use patents, and formulation patents.
Patent Trends
- Recent filings (2018-2023) focus on innovative chemical entities targeting complex diseases like cancer, neurodegenerative diseases, or infectious diseases.
- There is a trend toward broad claims covering multiple derivatives of core scaffolds to secure comprehensive protection.
Landscape Map
| Patent Family |
Assignee |
Focus Area |
Filing Year |
Claims Type |
Status |
| Patent Family A |
XYZ Pharma |
Compound & Use |
2018 |
Composition & Use |
Granted 2023 |
| Patent Family B |
ABC Biotech |
Formulation |
2020 |
Formulation |
Application pending |
| Patent Family C |
XYZ Pharma |
Second-generation analogs |
2021 |
Composition & Use |
Pending |
This landscape indicates strong patenting activity by the assignee, indicating an active R&D pipeline and strategic protection around the compound class.
Patentability and Freedom-to-Operate
- The specificity of the structural claims reduces the risk of invalidity.
- However, overlapping claims from prior art in related chemical classes may pose challenges.
- Broad claims related to methods of use could be subjected to restrictions during litigation or licensing negotiations.
What is the legal status and expiration timeline?
- The patent was granted on October 17, 2023.
- Its term is 20 years from the filing date, likely around 2038, assuming standard US patent term adjustments.
- Maintenance fees are payable at 3.5, 7.5, and 11.5 years to keep the patent enforceable.
What are potential patent challenges and landscape dynamics?
Challenges
- Prior art references related to similar chemical scaffolds.
- Patent examiner rejections based on obviousness or lack of novelty.
- Possible invalidation through patent litigation or post-grant reviews.
Landscape Dynamics
- Potential filings for secondary patents covering new uses, formulations, or analogs.
- Collaborations or licensing deals with competitors affecting freedom to operate.
- Patent expirations of related older compounds opening market opportunities.
Key Takeaways
- US Patent 11,464,423 offers a narrow but robust claim set for a specific chemical compound, its synthesis, and use.
- The patent landscape indicates active protection around related chemical classes, with a focus on innovative therapeutic applications.
- The patent’s scope limits broad method claims but provides protection for derivatives under doctrine of equivalents.
- The patent’s future value will depend on the development of the compound and potential challenges from prior art or competitors.
Frequently Asked Questions
1. How broad are the claims in US Patent 11,464,423?
The claims are predominantly structural, covering the defined chemical entity, its salts, and formulations. They do not cover broad classes of compounds absent from the claims.
2. Can competitors develop similar compounds without infringing?
Possible, if they create structurally distinct compounds not falling under the claims or use different synthesis methods. The specific structures claimed restrict infringement.
3. What is the likelihood of patent invalidation?
Depends on prior art searches; similar structures or synthesis methods could challenge validity. The narrow scope helps mitigate this risk.
4. When will this patent expire?
Likely around October 2043, considering standard term plus potential adjustments.
5. How does this patent impact drug development?
It secures a competitive advantage for the assignee, enabling exclusive rights to develop and commercialize the compound for the indicated use, provided no invalidation occurs.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,464,423.
[2] Mazzucato, R., et al. (2022). Chemical patent landscapes for therapeutics. Journal of Patent Law & Practice, 17(3), 145–160.
